Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
Rebecca Michelle DuBois · UNIVERSITY OF CALIFORNIA SANTA CRUZ · 2022 · $350,421 — PROJECT SUMMARY Human astroviruses (HAstV) are a leading cause of viral diarrhea in children. Divergent HAstV strains are associated with fatal human encephalitis. Currently, no vaccines or antiviral therapies exist for HAstV infections. Our goal is to identify sites of vulnerability (Achilles' heel…
Bidadi Venkataram Prasad · BAYLOR COLLEGE OF MEDICINE · 2022 · $642,137 — The long-term goal of our research is to understand the structural basis of the complex processes that regulate the replication cycle of rotaviruses (RVs), which are the global pathogens causing life-threatening infantile gastroenteritis. During 2013-2016, our studies have answered several questions…
John D Mountz · BIRMINGHAM VA MEDICAL CENTER · 2022 — The COVID-19 caused by the SARS-CoV-2 coronavirus infection is currently a global pandemic. The most important question is why some individuals produce rapid protective antibodies (Abs) and exhibit null or only mild symptoms, whereas others do not? A second urgent question is if a standard laborator…
David Scott Wilson · JOHNS HOPKINS UNIVERSITY · 2022 · $204,688 — 1. ABSTRACT/SUMMARY Given that the site of entry of SARS-CoV-2 is the respiratory mucosa, an effective vaccine for SARS-CoV-2 should initiate both humoral and respiratory mucosal immune responses. Although an intranasal subunit vaccine would be an ideal platform for SARS-CoV-2, transport across the …
Thomas M McIntyre · CLEVELAND CLINIC LERNER COM-CWRU · 2022 · $572,341 — Hypertension, for unknown reasons, is a primary co-morbidity risk factor for poor COVID-19 outcomes. SARS- Cov-2 breaches the lung blood-air barrier to spread among organs inducing endothelial cell dysfunction and multi-organ thromboembolism. ACE2 is the high affinity receptor for SARS-Cov-2 with TM…
Michael-Christopher Keogh · EPICYPHER, INC. · 2022 · $500,000 — PROJECT SUMMARY EpiCypher is collaborating with Dr. Jessica Tyler (an expert in aging, DNA repair and epigenetics), to develop CUT&RUssNTM (Cleavage Under Targets and Release Using single-stranded Nuclease), a first-in-class single-stranded DNA (ssDNA) mapping technology for research into the early…
Ricardo Rajsbaum · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · 2022 · $219,569 — The Severe Acute Respiratory Syndrome Coronavirus 2 (CoV-2) belongs to a family of pathogenic enveloped RNA viruses of the family Coronaviridae. The ongoing pandemic has caused a public health emergency worldwide, accompanied by dire health and economic consequences. There is evidence suggesting tha…
Wei-chiao Huang · POP BIOTECHNOLOGIES, INC · 2022 · $299,991 — PROJECT SUMMARY The coronavirus disease 2019 (COVID-19) global pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is unprecedented in our lifetime and has caused major social, economic and human suffering. Globally, there have been 76,858,506 confirmed cases, leading to …
Caitlin Jaime Couch · EMORY UNIVERSITY · 2022 · $46,036 — ABSTRACT As of August 2021, the coronavirus disease COVID-19, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has infected more than 200 million people across the globe, causing more than 600,000 deaths in the USA and 4.2 million worldwide. Though vaccines have become ava…
Shiqing Xu · TEXAS A&M UNIVERSITY · 2022 · $221,799 — PROJECT SUMMARY/ABSTRACT The current COVID-19 pandemic caused by SARS-CoV-2 has paralyzed much of the world. Encouragingly, a few COVID-19 vaccines have been developed and approved for human immunization. However, existing COVID-19 vaccines target the highly mutable membrane Spike protein of SARS-C…
Jianfa Bai · KANSAS STATE UNIVERSITY · 2022 · $79,038 — Project Summary: SARS-CoV-2 is a major human respiratory pathogen that can cause COVID-19, a disease with symptoms similar to those caused by Influenza A (Flu A) and Influenza B (Flu B) viruses. A few major SARS-CoV-2 variants of concern (VOC) have been identified and associated with increased trans…
TOMAS KIRCHHAUSEN · WASHINGTON UNIVERSITY · 2022 · $752,346 — The long term goal of this study is to understand how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of coronavirus disease 2019 (COVID-19), enters cells and how to block that process through the use of therapeutics. Like other enveloped viruses, SARS-CoV-2 cell entry…
Vijaya Mohan Rao Lella · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · 2022 · $183,750 — Emerging evidence indicates that the novel SARS-CoV-2 infection is associated with a high incidence of thrombotic complications. Thrombotic complications in COVID-19 patients are found to be life-threatening. Elevated D-dimers and disseminated intravascular coagulation (DIC) are strong predictors of…
Alexander Dickson · MICHIGAN STATE UNIVERSITY · 2022 · $307,308 — Project Summary Biology at the nanoscale is driven by molecular recognition. Cells are lined with receptors that recognize a myriad of biomolecules and transmit signals to the cell interior. This forms the basis of cell-cell communication that allows multicellular organisms to thrive. An understandi…
Guowei Wei · MICHIGAN STATE UNIVERSITY · 2022 · $540,234 — Project Summary Due to massive vaccination, coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been partially under control. However, emerging contagious variants such as Delta are still fueling new waves of infections around t…
Gary R Whittaker · CORNELL UNIVERSITY · 2022 · $235,500 — Project Summary/Abstract We propose to develop a subunit vaccine for SARS-CoV-2, using a structure-based approach targeting conserved and functionally essential domains in the stalk region of the viral spike protein. We expect our vaccine platform to be applicable and effective across a wide range o…
Sefika Banu Ozkan · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · 2022 · $424,111 — Summary Advanced sequencing technologies provide ever-increasing quantities of data about human genetic variation and viral evolution. However, predicting the outcomes of missense mutations in protein coding regions remains a challenge, creating a bottleneck in discriminating biomedically-relevant v…
Lanying Du · GEORGIA STATE UNIVERSITY · 2022 · $796,048 — Project Summary Viral subunit vaccines are safe and convenient, but generally suffer low efficacy. Our overall hypothesis is that an intrinsic limitation is associated with subunit vaccine designs in which artificially exposed surfaces of subunit vaccines contain epitopes unfavorable for vaccine eff…
MICHAEL A LYNES · CONNECTICUT CHILDREN'S MEDICAL CENTER · 2022 · $195,200 — PROJECT SUMMARY / ABSTRACT – No Changes From the Original Application In adults, SARS-CoV-2 infection exhibits a wide range of clinical outcomes, from asymptomatic and mild disease to severe viral pneumonia, respiratory distress, acute kidney injury, thrombotic disorders, and serious cardiac, cerebr…
Ula Y Hwang · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2024 · $1,475,648 — PROJECT ABSTRACT: Emergency care of older adults with Alzheimer's Disease and related dementias (ADRD) is suboptimal despite greater rates of emergency department (ED) use than for matched controls. Persons with dementia (PwD) are poorly identified in the ED, are more likely to have an avoidable ED…